CD22
CD22 (cluster of differentiation-22) is a cell surface sialic acid binding Ig-like lectin (SIGLEC2 or SIGLEC-2) that is involved in B-cell and B-cell interactions. It is mainly expressed on mature B cells and it is an immunoglobulin protein that contains six Ig-like C2-type domains and one Ig-like V-type domain in the extracellular portion for ligand binding and four cytoplasmic immunoreceptor tyrosine-based inhibitor motifs (ITIM) for downstream cellular signaling modulations.
CD22 interacts with ligands including Grb2, PTPN6, LYN, SHC1, and INPP5D with a high preference towards alpha-2,6-linked sialic acid. The ligand binding leads to the phosphorylation of CD22 cytoplasmic portion and mediates B cell receptor (BCR) signaling. Overall, CD22 is regarded as a regulatory molecule that tunes-down immune system activity and prevents the development of autoimmune diseases. Mutations and abnormal expressions of CD22 is often associated with refractory hematologic cancer and it is being exploited as a target for ADC-based immunotherapies using certain immunotoxins.
Entrez Gene ID: 933
UniProt ID: P20273
Catalog | Product name | Similar to | Antibody | Linker | Payload | Data sheet | Inquiry |
ADC-W-093 | Anti-CD22 (hLL2)-SN-38 ADC | Humanized Anti-CD22-antibody, hLL2 | SN-38 (7-ethyl-10-hydroxycamptothecin) | Inquiry | |||
ADC-W-177 | Anti-CD22 (clone 10F4v3)-BMPEO-DM1 ADC | Anti-CD22 antibody, clone # 10F4v3 | BMPEO (bis-maleimido-trioxyethylene glycol) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-180 | Anti-CD22 (clone 5E8)-SMCC-DM1 ADC | Anti-CD22 antibody, clone # 5E8 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-181 | Anti-CD22 (clone 7A2)-SMCC-DM1 ADC | Anti-CD22 antibody, clone # 7A2 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-182 | Anti-CD22 (clone 10F4v1)-SMCC-DM1 ADC | Humanized Anti-CD22 antibody, clone # 10F4v1 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-183 | Anti-CD22 (clone 10F4v2)-SMCC-DM1 ADC | Humanized Anti-CD22 antibody, clone # 10F4v2 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-184 | Anti-CD22 (clone 10F4v2)-Mc-MMAF ADC | Humanized Anti-CD22 antibody, clone # 10F4v2 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) | Inquiry | ||
ADC-W-185 | Anti-CD22 (clone 10F4v3)-SMCC-DM1 ADC | Humanized Anti-CD22 antibody, clone # 10F4v3 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-186 | Anti-CD22 (clone 10F4v3)-Mc-MMAF ADC | Humanized Anti-CD22 antibody, clone # 10F4v3 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) | Inquiry | ||
ADC-W-187 | Anti-CD22 (clone 10F4v3)-SPP-DM1 ADC | Humanized Anti-CD22 antibody, clone # 10F4v3 | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-188 | Anti-CD22 (clone 10F4v3)-Mc-VC-PABC-MMAE ADC | Humanized Anti-CD22 antibody, clone # 10F4v3 | MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE (Monomethyl auristatin E) | Inquiry | ||
ADC-W-189 | Anti-CD22 (clone 10F4)-SMCC-DM1 ADC | Anti-CD22 antibody, clone # 10F4 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-190 | Anti-CD22 (clone RFB4)-SMCC-DM1 ADC | Anti-CD22 antibody, clone # RFB4 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-191 | Anti-CD22 (clone RFB4)-Mc-VC-PABC-MMAF ADC | Anti-CD22 antibody, clone # RFB4 | MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAF (Monomethyl auristatin F) | Inquiry | ||
ADC-W-192 | Anti-CD22 (clone RFB4)-Mc-MMAF ADC | Anti-CD22 antibody, clone # RFB4 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) | Inquiry | ||
ADC-W-193 | Anti-CD22 (clone RFB4)-Mc-VC-PABC-MMAE ADC | Anti-CD22 antibody, clone # RFB4 | MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE (Monomethyl auristatin E) | Inquiry | ||
ADC-W-195 | Anti-CD22 (clone 10F4v1)-Mc-MMAF ADC | Anti-CD22 antibody, clone # 10F4v1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) | Inquiry | ||
ADC-W-216 | Anti-CD22 (10F4v3)-Mc-VC-PABC-MMAE ADC | Humanized Anti-CD22 lgG1 Antibody, 10F4v3 | MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE (Monomethyl auristatin E) | Inquiry | ||
ADC-W-217 | Anti-CD22 (10F4v3)-Mc-MMAF ADC | Humanized Anti-CD22 lgG1 Antibody, 10F4v3 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) | Inquiry | ||
ADC-W-331 | Anti-CD22 (clone RFB4)-MCC-DM1 ADC | Chimeric Anti-CD22 Antibody, clone # RFB4 | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-332 | Anti-CD22 (clone 10F4)-AcBut-Calicheamicin ADC | Humanized Anti-CD22 Antibody | AcBut [-(4' acetyl phenoxy) butanoic acid] | calicheamicin | Inquiry | ||
ADC-W-335 | Anti-CD22-Mc-MMAF ADC | Humanized Anti-CD22 Antibody | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) | Inquiry | ||
ADC-W-336 | Anti-CD22-MCC-DM1 ADC | Humanized Anti-CD22 Antibody | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-337 | Anti-CD22 (Pinatuzumab)-Mc-VC-PABC-MMAE ADC | Humanized Anti-CD22 Antibody, Pinatuzumab | MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE (Monomethyl auristatin E) | Inquiry | ||
ADC-W-338 | Anti-CD22 (Inotuzumab)-hydrazone-Calicheamicin ADC | Humanized Anti-CD22 Antibody, Inotuzumab | hydrazone | calicheamicin | Inquiry | ||
ADC-W-339 | Anti-CD22-DIBO-doxorubicin ADC | Humanized Anti-CD22 Antibody, Inotuzumab | DIBO (dibenzylcyclooctynol) | doxorubicin | Inquiry | ||
ADC-W-461 | Anti-CD22 (clone G5/44)-AcBut-CalichDMH ADC | inotuzumab ozogamicin | Humanized Anti-CD22 Antibody, clone # G5/44 | AcBut (4-(4-acetylphenoxy)butanoic acid) | CalichDMH | Inquiry | |
ADC-W-484 | Anti-CD22 (clone hu10F4)-MCC-DM1 ADC | hu10F4-MCC-DM1 | Humanized Anti-CD22 Antibody, hu10F4 | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | |
ADC-W-540 | Anti-CD22-Mc-VC-PAB-NMS249 ADC | Anti-CD22 Antibody | mc-VC-PAB (proteaselabile maleimido-caproyl-valine-citrulline-para-amino-benzyloxy carbonyl ) | NMS249 | Inquiry | ||
ADC-W-586 | Anti-CD22 (clone HB22.7)-saporin ADC | Anti-CD22 Antibody, clone # HB227 | saporin | Inquiry | |||
ADC-W-625 | Anti-CD22 (10F4v3)-SPP-DM1 ADC | Humanized Anti-CD22 lgG1 Antibody, 10F4v3 | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-626 | Anti-CD22 (10F4v3)-MCC-DM1 ADC | Humanized Anti-CD22 lgG1 Antibody, 10F4v3 | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-794 | Anti-CD22 (Bectumomab)-SMCC-DM1 ADC | Anti-CD22 IgG2a-Fab’ fragment , Bectumomab | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-795 | Anti-CD22 (Bectumomab)-SPDB-DM4 ADC | Anti-CD22 IgG2a-Fab’ fragment , Bectumomab | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) | Inquiry | ||
ADC-W-796 | Anti-CD22 (Bectumomab)-MC-MMAF ADC | Anti-CD22 IgG2a-Fab’ fragment , Bectumomab | MC (maleimidocaproyl) | MMAF | Inquiry | ||
ADC-W-797 | Anti-CD22 (Bectumomab)-MC-Vc-PAB-MMAE ADC | Anti-CD22 IgG2a-Fab’ fragment , Bectumomab | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE | Inquiry | ||
ADC-W-798 | Anti-CD22 (Bectumomab)-MC-Vc-PAB-SN38 ADC | Anti-CD22 IgG2a-Fab’ fragment , Bectumomab | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) | Inquiry | ||
ADC-W-799 | Anti-CD22 (Bectumomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | Anti-CD22 IgG2a-Fab’ fragment , Bectumomab | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA | Inquiry | ||
ADC-W-800 | Anti-CD22 (Moxetumomab pasudotox)-SMCC-DM1 ADC | Anti-CD22 Fv-disulfide stabilized antibody, Moxetumomab pasudotox | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-801 | Anti-CD22 (Moxetumomab pasudotox)-SPDB-DM4 ADC | Anti-CD22 Fv-disulfide stabilized antibody, Moxetumomab pasudotox | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) | Inquiry | ||
ADC-W-802 | Anti-CD22 (Moxetumomab pasudotox)-MC-MMAF ADC | Anti-CD22 Fv-disulfide stabilized antibody, Moxetumomab pasudotox | MC (maleimidocaproyl) | MMAF | Inquiry | ||
ADC-W-803 | Anti-CD22 (Moxetumomab pasudotox)-MC-Vc-PAB-MMAE ADC | Anti-CD22 Fv-disulfide stabilized antibody, Moxetumomab pasudotox | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE | Inquiry | ||
ADC-W-804 | Anti-CD22 (Moxetumomab pasudotox)-MC-Vc-PAB-SN38 ADC | Anti-CD22 Fv-disulfide stabilized antibody, Moxetumomab pasudotox | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) | Inquiry | ||
ADC-W-805 | Anti-CD22 (Moxetumomab pasudotox)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | Anti-CD22 Fv-disulfide stabilized antibody, Moxetumomab pasudotox | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA | Inquiry | ||
ADC-W-2521 | Anti-CD22 (Inotuzumab)-SMCC-DM1 ADC | Humanized Anti-CD22 IgG4-kappa antibody, Inotuzumab | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-2522 | Anti-CD22 (Inotuzumab)-SPDB-DM4 ADC | Humanized Anti-CD22 IgG4-kappa antibody, Inotuzumab | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) | Inquiry | ||
ADC-W-2523 | Anti-CD22 (Inotuzumab)-MC-MMAF ADC | Humanized Anti-CD22 IgG4-kappa antibody, Inotuzumab | MC (maleimidocaproyl) | MMAF | Inquiry | ||
ADC-W-2524 | Anti-CD22 (Inotuzumab)-MC-Vc-PAB-MMAE ADC | Humanized Anti-CD22 IgG4-kappa antibody, Inotuzumab | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE | Inquiry | ||
ADC-W-2525 | Anti-CD22 (Inotuzumab)-MC-Vc-PAB-SN38 ADC | Humanized Anti-CD22 IgG4-kappa antibody, Inotuzumab | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) | Inquiry | ||
ADC-W-2526 | Anti-CD22 (Inotuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | Humanized Anti-CD22 IgG4-kappa antibody, Inotuzumab | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA | Inquiry | ||
ADC-W-2527 | Anti-CD22-SMCC-DM1 ADC | Humanized Anti-CD22 IgG1 antibody | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-2528 | Anti-CD22-SPDB-DM4 ADC | Humanized Anti-CD22 IgG1 antibody | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) | Inquiry | ||
ADC-W-2529 | Anti-CD22-MC-Vc-PAB-MMAE ADC | Humanized Anti-CD22 IgG1 antibody | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE | Inquiry | ||
ADC-W-2530 | Anti-CD22-MC-Vc-PAB-SN38 ADC | Humanized Anti-CD22 IgG1 antibody | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) | Inquiry | ||
ADC-W-2531 | Anti-CD22-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | Humanized Anti-CD22 IgG1 antibody | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA | Inquiry | ||
ADC-W-2532 | Anti-CD22 (Pinatuzumab)-SMCC-DM1 ADC | Humanized Anti-CD22 IgG1-kappa antibody, Pinatuzumab | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) | Inquiry | ||
ADC-W-2533 | Anti-CD22 (Pinatuzumab)-SPDB-DM4 ADC | Humanized Anti-CD22 IgG1-kappa antibody, Pinatuzumab | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) | Inquiry | ||
ADC-W-2534 | Anti-CD22 (Pinatuzumab)-MC-MMAF ADC | Humanized Anti-CD22 IgG1-kappa antibody, Pinatuzumab | MC (maleimidocaproyl) | MMAF | Inquiry | ||
ADC-W-2535 | Anti-CD22 (Pinatuzumab)-MC-Vc-PAB-SN38 ADC | Humanized Anti-CD22 IgG1-kappa antibody, Pinatuzumab | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) | Inquiry | ||
ADC-W-2536 | Anti-CD22 (Pinatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | Humanized Anti-CD22 IgG1-kappa antibody, Pinatuzumab | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA | Inquiry |
If you can’t find your product on this list? Please directly send email to info@creative-biolabs.com
For Research Use Only. NOT FOR CLINICAL USE.
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.